Analysis Of The Effect Of Thymopentin Adjuvant Therapy On Clinical Efficacy And Inflammatory Factors In Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease

Objective:To investigate the immunomodulatory effect and value of thymopentin adjuvant therapy for acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A retrospective method was used to collect patients with COPD in the Respiratory and Critical Care Medicine of the First Hospital of Jilin University from January 2015 to November 2020.Among them,a total of75 patients met the inclusion criteria,including 32 patients in the conventional treatment group and 43 patients in the conventional treatment combined with thymopentin group.The differences between the two groups were compared in terms of length of stay,average hospitalization cost,symptom remission time,efficacy evaluation,etc.Results:1.There were no significant differences between the two groups in age(P=0.251),gender(P=0.465),duration of disease(P=0.295),disease severity assessment(COPD assessment test,P=0.108),complicated hypertension(P=0.249)and complicated diabetes(P=1.000).2.There were significant differences in length of hospital stay(P=0.024),average hospitalization cost(P=0.001),symptom remission time(P= 0.016),duration of use of non-invasive ventilator(P=0.011),the time for WBC to return to normal(P=0.001),the time for CRP to return to normal(P= 0.020)and the time for PCT to return to normal(P= 0.006)between the two groups.3.The difference in efficacy assessment between the two groups(P=0.045)was statistically significant.Conclusion:1.The thymopentin combined with conventional treatment of COPD can help control the disease progression,speed up the recovery of the disease,and has a good effect.2.The thymopentin combined with conventional treatment of COPD can shorten the length of hospital stay and reduce the cost of hospital stay.